GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

Now Viewing

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on GPRC5D as an emerging target in multiple myeloma. Early data with the GPRC5D-targeted bispecific antibody talquetamab demonstrates response rates around 60% to 65%. However, progression-free survival appears shorter than with B-cell maturation antigen–directed therapies.

A key toxicity is on-target, off-tumor effects causing dysgeusia and weight loss. This impacts quality of life significantly. Dose reductions or schedule adjustments (eg, biweekly vs weekly dosing) may mitigate these adverse effects. Ongoing trials are also evaluating talquetamab combinations, like with pomalidomide to improve efficacy or with daratumumab, which allows extended talquetamab dosing intervals. Such combinations can overcome high-risk disease. Further follow-up is needed.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.